Cadrenal Therapeutics, INC 8-K filings

Cadrenal Therapeutics has successfully raised $4.7 million by inducing warrant holders to exercise existing warrants, and in return, issued new warrants.

Cadrenal Therapeutics has raised $5.1 million by selling 391,243 shares of common stock through its at-the-market facility.

Cadrenal Therapeutics released an investor presentation detailing the progress of their Phase 3-ready drug candidate, tecarfarin, and its potential in treating underserved patient populations.

Cadrenal Therapeutics has regained compliance with Nasdaq listing rules after its stock price closed at or above $1.00 for ten consecutive days.

Cadrenal Therapeutics has executed a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement.

Cadrenal Therapeutics will implement a 1-for-15 reverse stock split of its common stock effective August 20, 2024, to comply with Nasdaq's minimum bid price requirement.

Cadrenal Therapeutics is collaborating with Abbott to advance the development of tecarfarin, a novel anticoagulant, for patients with left ventricular assist devices (LVADs).

Cadrenal Therapeutics and Abbott are collaborating to advance the study of tecarfarin, a novel anticoagulant, for patients with recently implanted left ventricular assist devices (LVADs).

Cadrenal Therapeutics' stockholders approved an increase in the share pool for its equity incentive plan, authorized a reverse stock split, and elected directors at its 2024 annual meeting.

Cadrenal Therapeutics has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Cadrenal Therapeutics has been granted FDA Orphan Drug Designation for tecarfarin to prevent blood clots in patients with mechanical circulatory support devices, potentially providing seven years of market exclusivity.

Cadrenal Therapeutics has entered into an agreement with H.C. Wainwright & Co. to sell up to $5.14 million of its common stock through an at-the-market offering.

Cadrenal Therapeutics broadens the development of its anticoagulant drug, tecarfarin, to include additional rare cardiovascular conditions, increasing its market potential.

Cadrenal Therapeutics has received a 180-day extension from Nasdaq to meet the minimum bid price requirement for continued listing.

Cadrenal Therapeutics received a notice from Nasdaq for not maintaining a minimum share price of $1.00, putting its listing at risk.

Cadrenal Therapeutics has appointed Jeffrey Cole as its Chief Operating Officer to oversee manufacturing, commercialization, and partnering activities for their lead drug candidate, tecarfarin.